Inhibitor

(redirected from DPP-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
McGraw-Hill Dictionary of Architecture and Construction. Copyright © 2003 by McGraw-Hill Companies, Inc.
References in periodicals archive ?
(2) In particular, the introduction of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors over the past several years has produced an area of some clinical ambiguity, due to the lack of randomized controlled trials (RCTs) comparing their efficacy.
Overall, the median weight gain of 1.5 kg was observed in the insulin group, with no change of median weight in DPP-4 inhibitor group.
In the DPP-4 inhibitor group, most exposures (49.7%) were to sitagliptin, 18.9% were to linagliptin, 10.4% were to saxagliptin, and the remaining exposures were to alogliptin, gemigliptin, teneligliptin, anagliptin, evogliptin, and trelagliptin (0.1%-4.7%).
There was no reduction in risk of death from a cardiovascular event for the drugs DPP-4 inhibitors.
DPP-4 inhibitors act in concert to stimulate insulin secretion, leading to improved glucose levels.
Firstly, DPP-4 inhibitors increase NO release, but decrease the release of glucagon.
De Boer, "Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure," Cardiovascular Diabetology, vol.
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.
[27] Sitagliptin, a DPP-4 inhibitor, presents an alternative therapeutic strategy for patients with type 2 DM and, in general, shows significant improvements in glycemic control.
That's where DPP-4 inhibitor sitagliptin comes to the rescue.